Your browser is no longer supported. Please, upgrade your browser. Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
GALE [NASD]
Galena Biopharma, Inc.
Index- P/E- EPS (ttm)-0.70 Insider Own0.40% Shs Outstand121.45M Perf Week10.70%
Market Cap251.40M Forward P/E- EPS next Y-0.31 Insider Trans2.53% Shs Float120.77M Perf Month9.52%
Income-77.20M PEG- EPS next Q-0.11 Inst Own18.30% Short Float16.27% Perf Quarter-1.43%
Sales7.40M P/S33.97 EPS this Y-60.40% Inst Trans-2.90% Short Ratio13.25 Perf Half Y-14.81%
Book/sh0.26 P/B7.96 EPS next Y13.90% ROA-90.70% Target Price6.00 Perf Year-40.69%
Cash/sh0.20 P/C10.22 EPS next 5Y- ROE-276.30% 52W Range1.56 - 7.77 Perf YTD-58.27%
Dividend- P/FCF- EPS past 5Y4.90% ROI-225.80% 52W High-73.36% Beta1.14
Dividend %- Quick Ratio0.90 Sales past 5Y- Gross Margin85.10% 52W Low32.69% ATR0.13
Employees60 Current Ratio0.90 Sales Q/Q33.30% Oper. Margin- RSI (14)56.71 Volatility5.48% 6.59%
OptionableYes Debt/Eq0.30 EPS Q/Q54.50% Profit Margin- Rel Volume3.32 Prev Close1.86
ShortableYes LT Debt/Eq0.17 EarningsNov 03 AMC Payout- Avg Volume1.48M Price2.07
Recom2.40 SMA206.15% SMA504.68% SMA200-20.12% Volume4,923,498 Change11.29%
Nov-20-14Reiterated MLV & Co Buy $3 → $5
Aug-22-14Reiterated MLV & Co Buy $5 → $3.50
Aug-12-14Reiterated Needham Buy $9 → $7
Feb-03-14Reiterated Noble Financial Buy $4 → $6
Jan-21-14Reiterated Maxim Group Buy $9 → $11
Jan-08-14Reiterated Maxim Group Buy $6 → $9
Nov-26-13Initiated Oppenheimer Outperform $6
Mar-25-13Initiated Needham Buy $3.50
Nov-28-12Initiated Aegis Capital Buy $6
Nov-05-12Initiated Maxim Group Buy $5
Oct-25-12Initiated MLV & Co Buy $6
Jun-04-12Initiated Cantor Fitzgerald Buy $4
Nov-20-14 04:21PM  GALENA BIOPHARMA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhib EDGAR Online
04:20PM  Galena Biopharma Announces Purchase Agreement for Up to $55.0 Million With Lincoln Park Capital Fund, LLC GlobeNewswire
10:05AM  UPDATE: MLV & Co Reiterates On Galena Biopharma As External Risks Have Subsided Benzinga
Nov-18-14 07:05AM  Galena Biopharma Completes Enrollment in GALE-401 (Anagrelide Controlled Release) Phase 2 Clinical Trial GlobeNewswire
Nov-14-14 01:04PM  GALENA BIOPHARMA, INC. Financials EDGAR Online Financials
Nov-13-14 07:05AM  Galena Biopharma to Present at the Stifel 2014 Healthcare Conference GlobeNewswire
Nov-11-14 07:05AM  Galena Biopharma Doses First Patient in Phase 2 Clinical Trial With NeuVax(TM) (nelipepimut-S) in Combination With Herceptin(R) (trastuzumab) to Treat High-Risk HER2 3+ or HER2 Gene-Amplified Breast Cancer Patients GlobeNewswire
Nov-07-14 05:26PM  GALENA BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
04:28PM  Another lackluster session for major equities Yahoo Finance Blogs
07:05AM  Galena Biopharma Presents GALE-301 (Folate Binding Protein Immunotherapy) Phase 2a Clinical Trial Data at the Society for Immunotherapy of Cancer (SITC) 29th Annual Meeting GlobeNewswire
Nov-05-14 04:38PM  GALENA BIOPHARMA, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online
Nov-04-14 07:05AM  Galena Biopharma to Present GALE-301 (Folate Binding Protein) Phase 2a Clinical Trial Data at the Society for the Immunotherapy of Cancer (SITC) 29th Annual Meeting on Friday, November 7, 2014 GlobeNewswire
Nov-03-14 05:21PM  Galena Biopharma beats 3Q profit forecasts AP -6.83%
04:33PM  GALENA BIOPHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Ex EDGAR Online
04:20PM  Galena Biopharma Reports Third Quarter 2014 Results GlobeNewswire
02:00PM  Heat Biologics Takes a New Approach to Immunotherapy Accesswire
07:07AM  Q3 2014 Galena Biopharma Inc Earnings Release - After Market Close CCBN
Oct-27-14 07:05AM  Galena Biopharma to Report Third Quarter 2014 Financial Results on Monday, November 3, 2014 GlobeNewswire +5.26%
Oct-14-14 07:05AM  Galena Biopharma Receives Notice of Allowance of Improvement Patent for NeuVax(TM) (nelipepimut-S) in Japan GlobeNewswire +5.06%
Oct-09-14 06:51AM  Weakness Seen in Galena Biopharma (GALE) Estimates: Should You Stay Away? Zacks
Oct-08-14 07:05AM  Galena Biopharma Announces Notice of Allowance of U.S. Patent Application for NeuVax(TM) (nelipepimut-S) Combination GlobeNewswire
Sep-26-14 05:18PM  GALENA BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
Sep-25-14 04:15PM  Galena Biopharma Announces Release of Special Committee Report and Hosting of a Conference Call to Provide a Corporate Update GlobeNewswire
Sep-18-14 04:45PM  GALENA BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
Sep-09-14 07:05AM  Galena Biopharma Doses First Patient in GALE-401 (Anagrelide Controlled Release) Phase 2 Clinical Trial GlobeNewswire
Sep-03-14 07:05AM  Galena Biopharma to Present at the Rodman & Renshaw 16th Annual Global Investment Conference GlobeNewswire
Aug-27-14 11:36AM  Why Galena Biopharma (GALE) Stock Is Spiking Today at TheStreet +5.98%
07:59AM  UPDATE: MLV & Co Reiterates On Galena Biopharma On Positive Long-Term Outlook Benzinga
Aug-25-14 08:48AM  Galena Fires CEO Ahn, Offers No Parting Gifts at TheStreet
Aug-22-14 04:47PM  GALENA BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Stateme EDGAR Online
08:48AM  Biotech Stock Mailbag: Threshold, Galena, CytRx at TheStreet
Aug-21-14 07:16AM  Galena CEO Fired Following Stock-Promotions Scandal at TheStreet -5.17%
07:05AM  Galena Biopharma Appoints Mark W. Schwartz, Ph.D., as President and Chief Executive Officer GlobeNewswire
Aug-15-14 07:22AM  Biotech Stock Mailbag: Exact Sciences, Galena, Amgen at TheStreet
Aug-11-14 10:20PM  Intercept Pharma Soars On Positive Liver Drug Data at Investor's Business Daily
04:35PM  GALENA BIOPHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Ex EDGAR Online
04:35PM  Galena Biopharma Reports Second Quarter 2014 Results GlobeNewswire
07:07AM  Q2 2014 Galena Biopharma Inc Earnings Release - After Market Close CCBN
Jul-29-14 07:05AM  Galena Biopharma to Report Second Quarter 2014 Financial Results on Monday, August 11, 2014 GlobeNewswire
Jul-28-14 12:34PM  Galectin Pays Stock Promoters to Entice Retail Investors at TheStreet
Jul-22-14 04:52PM  GALENA BIOPHARMA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhib EDGAR Online
04:24PM  Galena Stock: What to Watch for at Motley Fool
09:55AM  Galena 'stands little chance' of improving Zuplenz sales, TheStreet says at theflyonthewall.com
09:41AM  Galena Gives Sales Team Another Useless Product to Promote at TheStreet
07:21AM  Galena enters into licensing agreement with MonoSol Rx theflyonthewall.com
07:15AM  MonoSol Rx Enters Into Exclusive Licensing Agreement With Galena Biopharma for Zuplenz(R) Oral Soluble Film GlobeNewswire
07:05AM  Galena Biopharma Enters Into Definitive Agreement to License U.S. Rights for Zuplenz(R) (ondansetron) Oral Soluble Film GlobeNewswire
Jul-07-14 06:30PM  Biotech Accused in Stock-Pump Scheme at Barrons.com
Jul-02-14 04:41PM  GALENA BIOPHARMA, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders EDGAR Online
09:49AM  Trade-Ideas: Galena Biopharma (GALE) Is Today's "Perilous Reversal" Stock at TheStreet
Jul-01-14 07:05AM  Galena Biopharma Receives Notice of Allowance of Broad U.S. Patent for NeuVax(TM) (nelipepimut-S) GlobeNewswire +6.21%
Jun-20-14 06:04PM  Why Shorts Are Taking Aim at This Marijuana Stock at Motley Fool
Jun-19-14 07:05AM  Galena Biopharma to Present at the 9th Annual JMP Securities Healthcare Conference GlobeNewswire
Jun-18-14 10:01AM  3 Things That Actually Matter for Galena Investors at Motley Fool
09:52AM  Stock To Watch: Galena Biopharma (GALE) In Perilous Reversal at TheStreet
Jun-17-14 02:10PM  Why Galena Biopharma Inc. Shares Spiked Higher at Motley Fool +6.64%
07:05AM  Galena Biopharma Completes Enrollment in GALE-301 Phase 2a Clinical Trial in Ovarian and Endometrial Cancers GlobeNewswire
Jun-16-14 10:22AM  Galena Biopharma (GALE) Marked As A Dead Cat Bounce Stock at TheStreet
08:00AM  Theralase's Cancer Technology Demonstrates Vaccine-Like Properties Accesswire
Jun-13-14 10:11AM  Galena Promoting Experimental Breast Cancer Drug With Faux News Articles Again at TheStreet -6.77%
Jun-11-14 06:11PM  Is It Time to Buy Galena? at Motley Fool
Jun-10-14 05:16PM  Why Achillion Pharmaceuticals, Receptos, and Galena Biopharma Are Today's 3 Best Stocks at Motley Fool +16.79%
Jun-06-14 10:32AM  Biotech Stock Hate Mailbag: The Hostile React-o-Meter Meltdown Edition at TheStreet
Jun-02-14 07:05AM  Galena Biopharma Presents GALE-301 Phase 1 Data at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting GlobeNewswire
May-30-14 07:05AM  Galena Biopharma to Present at the Jefferies 2014 Global Healthcare Conference GlobeNewswire
May-29-14 07:00AM  The Seven Deadly Sins of Biotech Investing at TheStreet
May-23-14 07:05AM  Galena Biopharma to Present at the Marcum MicroCap Conference GlobeNewswire +6.48%
May-21-14 06:51PM  Lightning Round: Sodastream, Amazon & more at CNBC
07:05AM  Galena Biopharma to Present GALE-301 Phase 1 Data at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting GlobeNewswire
May-14-14 03:36PM  Lion Biotechnologies says received SEC subpoena related to Galena at theflyonthewall.com
03:35PM  SEC Casting Wide Net in Galena Investigation at TheStreet
May-07-14 02:02PM  Why Galena Biopharma Inc. Shares Surged Higher at Motley Fool
May-06-14 06:58PM  On The Fly: After Hours Movers at theflyonthewall.com -6.82%
05:47PM  Abstral Growth and a Warrant Valuation Benefit Shrink Galena's Q1 Loss by 73% at Motley Fool
04:40PM  GALENA BIOPHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Ex EDGAR Online
04:35PM  Galena Biopharma Reports First Quarter 2014 Results GlobeNewswire
07:07AM  Q1 2014 Galena Biopharma Inc Earnings Release - After Market Close CCBN
May-01-14 10:00PM  GALENA 96 HOUR DEADLINE ALERT: Approximately 96 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors of Deadline in Securities Class Action Lawsuit Against Galena Biopharma, Inc. - GALE Marketwired
01:35PM  GALENA BIOPHARMA, INC. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of Class Action Against GALENA BIOPHARMA, INC. and Its Board and a Lead Plaintiff Deadline of May 5, 2014 Business Wire
Apr-30-14 07:05AM  Galena Biopharma to Present at the 39th Annual Deutsche Bank Health Care Conference GlobeNewswire
Apr-28-14 02:00PM  Why Galena Biopharma Inc. Shares Briefly Rocketed Higher at Motley Fool
Apr-26-14 07:31AM  3 Stocks That Soared Stupendously This Week at Motley Fool
Apr-25-14 01:38PM  SHAREHOLDER ALERT: Brower Piven Announces the Filing of a Class Action Lawsuit Against Galena BioPharma, Inc. Expanding the Class Period to Include May 9, 2013 and March 17, 2014, Inclusive, and Encourages Investors to Inquire About the Lea GlobeNewswire
07:05AM  Galena Biopharma to Report First Quarter 2014 Financial Results on Tuesday, May 6, 2014 GlobeNewswire
Apr-24-14 07:05AM  Galena Biopharma Research Pioneer Presented With 2014 Award for Excellence in Technology Transfer GlobeNewswire
Apr-23-14 07:15PM  GALENA BIOPHARMA, INC. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of Class Action Against GALENA BIOPHARMA, INC. and Its Board and a Lead Plaintiff Deadline of May 5, 2014 -- GALE GlobeNewswire +10.10%
Apr-22-14 05:06PM  EQUITY ALERT: Rosen Law Firm Reminds Galena Biopharma, Inc. Investors of Important May 5, 2014 Class Action Deadline -- GALE GlobeNewswire +12.43%
10:32AM  INVESTOR ALERT: Law Offices of Howard G. Smith Announces an Expanded Class Period in the Shareholder Lawsuit against Galena Biopharma, Inc. Business Wire
Apr-16-14 07:56PM  Hagens Berman: Galena Biopharma Investigation Proceeds in Light of May 5, 2014 Lead Plaintiff Deadline in Securities Fraud Class Actions PR Newswire +6.90%
Apr-14-14 11:16AM  Are These Three Biotech Companies Still Worth A Gamble? at Seeking Alpha -8.74%
Apr-11-14 06:28PM  Lieff Cabraser Reminds Galena Biopharma, Inc. Investors of Upcoming Deadline in Class Action Litigation GALE Business Wire
04:14PM  SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Galena Biopharma, Inc. and Certain Officers - GALE PR Newswire
Apr-10-14 12:15PM  GALENA BIOPHARMA, INC. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of Class Action Against GALENA BIOPHARMA, INC. and Its Board and a Lead Plaintiff Deadline of May 5, 2014 -- GALE Business Wire -7.30%
Apr-09-14 05:14PM  SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 from Investment in Galena Biopharma, Inc. to Contact Brower Piven Before the May 5, 2014 Lead Plaintiff Deadline Business Wire
Apr-08-14 09:54AM  The other 'rotation' keeps stocks spinning at CNBC
Apr-07-14 05:23PM  Hagens Berman Notifies Investors of Extended Class Period and May 5, 2014 Lead Plaintiff Deadline in Galena Biopharma, Inc. Securities Fraud Class Actions PR Newswire
Apr-03-14 01:03PM  INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against Galena Biopharma, Inc. Business Wire
07:05AM  Galena Biopharma to Present at the 13th Annual Needham Healthcare Conference GlobeNewswire
Mar-31-14 01:37PM  Hagens Berman Reminds Galena Biopharma, Inc. Investors of May 5, 2014, Lead Plaintiff Deadline and Continued Securities Fraud Investigation Business Wire +12.61%
09:49AM  Today's Dead Cat Bounce Stock: Galena Biopharma (GALE) at TheStreet
Galena Biopharma, Inc., a biopharmaceutical company, focuses on developing and commercializing oncology treatments that address major unmet medical needs to advance cancer care. Its commercial product includes Abstral, a sublingual tablet, which is used as treatment option for breakthrough cancer pain in patients. The company's lead product candidate comprise NeuVax (nelipepimut-S or E75), which has completed Phase III clinical trials for preventing the recurrence of breast cancer; and Phase IIb clinical trials in combination with Herceptin for the treatment of breast cancer. It also develops GALE-301 or Folate Binding Protein (FBP), a therapeutic target that has completed Phase II clinical trials for the treatment of ovarian and endometrial cancers; and GALE-401 (Anagrelide CR), which has completed Phase I studies for the treatment of essential thrombocythemia. Galena Biopharma, Inc. has strategic partnership with Dr. Reddy's Laboratories Ltd. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Galena Biopharma, Inc. in September 2011. Galena Biopharma, Inc. was founded in 2003 and is based in Lake Portland, Oregon.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Chin RichardDirectorFeb 12Option Exercise1.59187,500297,625187,500Feb 13 07:56 PM
Chin RichardDirectorFeb 12Sale4.33187,500812,4380Feb 13 07:56 PM
Nisi RudolphDirectorFeb 07Buy4.9420,00098,74223,500Feb 13 08:22 PM
GALLIKER STEPHEN SDirectorFeb 03Option Exercise1.33300,000397,500310,000Feb 05 07:41 PM
GALLIKER STEPHEN SDirectorFeb 03Sale4.18300,0001,253,04010,000Feb 05 07:41 PM
Hillsberg SanfordDirectorJan 30Option Exercise1.29250,000321,500267,974Jan 31 08:32 PM
Chin RichardDirectorJan 30Option Exercise0.7675,00057,25075,000Feb 03 06:21 PM
Chin RichardDirectorJan 30Sale5.5875,000418,7550Feb 03 06:21 PM
SCHWARTZ MARK W.EVP & Chief Operating OfficerJan 30Sale5.57100,000556,500409,665Jan 31 08:44 PM
Hillsberg SanfordDirectorJan 30Sale5.41250,0001,352,50017,974Jan 31 08:32 PM
Nisi RudolphDirectorJan 29Option Exercise1.42250,000355,000253,500Jan 31 08:12 PM
Nisi RudolphDirectorJan 29Sale5.28250,0001,320,0003,500Jan 31 08:12 PM
Ahn Mark JPresident & CEOJan 27Option Exercise1.32796,7651,054,254918,529Jan 29 09:34 PM
Ahn Mark JPresident & CEOJan 27Sale4.83796,7653,848,375113,764Jan 29 09:34 PM
KRIEGSMAN STEVEN ADirectorJan 23Option Exercise1.56150,000233,500155,000Apr 09 08:44 PM
KRIEGSMAN STEVEN ADirectorJan 23Sale5.92150,000888,5405,000Apr 09 08:44 PM
KRIEGSMAN STEVEN ADirectorJan 22Option Exercise1.09250,000272,000255,000Jan 22 09:14 PM
KRIEGSMAN STEVEN ADirectorJan 22Sale6.13250,0001,532,5005,000Jan 22 09:14 PM
KRIEGSMAN STEVEN ADirectorJan 17Option Exercise0.85200,000170,000205,000Jan 22 09:14 PM
Hillsberg SanfordDirectorJan 17Sale6.93200,0001,385,000110,447Jan 22 09:22 PM
KRIEGSMAN STEVEN ADirectorJan 17Sale7.00200,0001,400,0005,000Jan 22 09:14 PM
Nisi RudolphDirectorJan 17Sale6.90200,0001,380,0003,500Jan 22 08:55 PM
Nisi RudolphDirectorJan 15Option Exercise1.02200,000203,000203,500Jan 22 08:55 PM